SG3 Management’s Heron Therapeutics HRTX Stock Holding History

SG3 Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-65,000	Closed	-$593K	–	1143
2021 Q4	$593K	Buy	+65,000	New	+$664K	0.01%	596

Other funds holding HRTX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

SG3 Management's HRTX Position: Q1 2022 in Review

SG3 Management sold out of Heron Therapeutics (HRTX) in Q1 2022, closing a stake of 27,904 shares — an estimated $255K sold.

SG3 Management first reported a position in HRTX in Q4 2021 and held it in 1 quarter. The position peaked at $255K in Q4 2021. 186 funds tracked by Wall St. Rank hold HRTX as of Q1 2022.

SG3 Management reported no remaining Heron Therapeutics position as of Q1 2022 after selling out during the quarter.
SG3 Management sold 27,904 Heron Therapeutics shares in Q1 2022, an estimated $255K.
SG3 Management first reported a position in Heron Therapeutics in Q4 2021 and held it in 1 quarter.
SG3 Management's Heron Therapeutics position peaked at $255K in Q4 2021.
186 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.